



Medexus Pharmaceuticals Inc.

**Report of Voting Results for Annual Meeting of Shareholders on September 15, 2022
(National Instrument 51-102 – *Continuous Disclosure Obligations*, section 11.3)**

Medexus Pharmaceuticals Inc. (**Company**) held an annual meeting of shareholders on September 15, 2022. Shareholders holding 31.80% of the issued and outstanding common shares of Medexus Pharmaceuticals Inc. (**Company**) as of the record date of July 29, 2022 were represented in person or by proxy at the meeting.

Voting on all matters at the meeting was conducted by ballot. All matters put to a ballot were passed with the requisite shareholder approval. The detailed results are set out below.

Election of directors

(a) Each of the six nominees in the Company’s management information circular dated August 5, 2022 were elected to serve until the next annual meeting of shareholders of the Company or until their successors are duly elected or appointed.

(b) The percentage of votes cast for, cast against, and withheld from the vote are set out below opposite the name of each director.

Name	For (#)	Withheld (#)	Against (#)
Ken d’Entremont	99.43% (5,537,745)	0.00% (–)	0.57% (31,837)
Benoit Gravel	99.16% (5,522,737)	0.02% (1,000)	0.82% (45,845)
Adele Gulfo	99.18% (5,523,727)	0.00% (10)	0.82% (45,845)
Michael Mueller	99.16% (5,522,737)	0.02% (1,000)	0.82% (45,845)
Stephen Nelson	99.16% (5,522,727)	0.02% (1,010)	0.82% (45,845)
Peter van der Velden	99.56% (5,545,245)	0.00% (–)	0.44% (24,337)

Appointment of auditors

(a) The appointment of PricewaterhouseCoopers LLP as auditors of the Company for the ensuing year and the authorization of the directors to fix their remuneration as such was passed with the requisite shareholder approval.

(b) The percentage of votes cast for and withheld from the vote are set out below.

Matter	For (#)	Withheld (#)
Appointment of PricewaterhouseCoopers LLP, Chartered Accountants as auditors of the Company for the ensuing year and authorizing the directors to fix their remuneration	97.07% (6,156,395)	2.93% (185,845)

Approval of new long-term incentive plan

(a) The approval of resolutions to adopt a new equity compensation plan for the Corporation, as more fully described in the Company's management information circular dated August 5, 2022, was passed with the requisite shareholder approval.

(b) The percentage of votes cast for and against are set out below.

Matter	For (#)	Against (#)
To consider and approve resolutions to adopt a new equity compensation plan for the Company, as more fully described in the Company's management information circular dated August 5, 2022	98.01% (5,458,859)	1.99% (110,723)

Executed by the undersigned on behalf of the Company on September 15, 2022.

Medexus Pharmaceutical Inc.

By: /s/ Ian Craig Wildgoose Brown
Name: Ian Craig Wildgoose Brown
Title: Corporate Secretary